LOWER PRICE/FACTORY CAS NO.910463-68-2

semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk, Denmark. Semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in treating type 2 diabetes. Novo Nordisk has completed six PChemicalbookhaseIIIa studies for its once-weekly injection of Sommarlutide and submitted a new drug registration application to the U.S. Food and Drug Administration (FDA) on December 5, 2016. An application for Marketing Authorization (MAA) has also been submitted to the European Medicines Agency (EMA). On the other hand, a once-daily oral formulation of sommarlutide is currently in phase III.our advantage is high quanlity, best price, fast speed.

Shanghai Hope-Chem Co,Ltd,founded in 2014,is a high-tech company integrating R&D,manufacturing and marketing.We

have three GMP plants in Henan,Anhui,Shandong province,covering about 43,000m²and more than 100 employees now.

among them over 80%skilled engineers and technicians with college degree.

our main products are APls and intermediates of antiviral drug substances and anti-inflammatory,analgesic,non-steroida

pharmaceuticals.Supported by the advanced,high standard and strict requirements of the manufacturing system,our productshave been exported all throughout the world including Europe,Asia,South America,and Africa